Continuous Pneumatic Regulation of Tracheal Cuff Pressure to Decrease Ventilator-associated Pneumonia in Trauma Patients Who Were Mechanically Ventilated: The AGATE Multicenter Randomized Controlled Study.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
08 2021
Historique:
received: 22 09 2020
revised: 17 02 2021
accepted: 01 03 2021
pubmed: 18 3 2021
medline: 4 1 2022
entrez: 17 3 2021
Statut: ppublish

Résumé

Ventilator-associated pneumonia (VAP) is the most frequent health care-associated infection in severely ill patients, and aspiration of contaminated oropharyngeal content around the cuff of the tracheal tube is the main route of contamination. Is continuous regulation of tracheal cuff pressure using a pneumatic device superior to manual assessment three times daily using a portable manometer (routine care) in preventing VAP in patients with severe trauma? In this open-label, randomized controlled superiority trial conducted in 13 French ICUs, adults (age ≥ 18 years) with severe trauma (Injury Severity Score > 15) and requiring invasive mechanical ventilation for ≥ 48 h were enrolled. Patients were randomly assigned (1:1) via a secure Web-based random number generator in permuted blocks of variable sizes to one of two groups according to the method of tracheal cuff pressure control. The primary outcome was the proportion of patients developing VAP within 28 days following the tracheal intubation, as determined by two assessors masked to group assignment, in the modified intention-to-treat population. This study is closed to new participants. A total of 434 patients were recruited between July 31, 2015, and February 15, 2018, of whom 216 were assigned to the intervention group and 218 to the control group. Seventy-three patients (33.8%) developed at least one episode of VAP within 28 days following the tracheal intubation in the intervention group compared with 64 patients (29.4%) in the control group (adjusted subdistribution hazard ratio, 0.96; 95% CI, 0.76-1.20; P = .71). No serious adverse events related to the use of the pneumatic device were noted. Continuous regulation of cuff pressure of the tracheal tube using a pneumatic device was not superior to routine care in preventing VAP in patients with severe trauma. ClinicalTrials.gov; No.: NCT02534974; URL: www.clinicaltrials.gov.

Sections du résumé

BACKGROUND
Ventilator-associated pneumonia (VAP) is the most frequent health care-associated infection in severely ill patients, and aspiration of contaminated oropharyngeal content around the cuff of the tracheal tube is the main route of contamination.
RESEARCH QUESTION
Is continuous regulation of tracheal cuff pressure using a pneumatic device superior to manual assessment three times daily using a portable manometer (routine care) in preventing VAP in patients with severe trauma?
STUDY DESIGN AND METHODS
In this open-label, randomized controlled superiority trial conducted in 13 French ICUs, adults (age ≥ 18 years) with severe trauma (Injury Severity Score > 15) and requiring invasive mechanical ventilation for ≥ 48 h were enrolled. Patients were randomly assigned (1:1) via a secure Web-based random number generator in permuted blocks of variable sizes to one of two groups according to the method of tracheal cuff pressure control. The primary outcome was the proportion of patients developing VAP within 28 days following the tracheal intubation, as determined by two assessors masked to group assignment, in the modified intention-to-treat population. This study is closed to new participants.
RESULTS
A total of 434 patients were recruited between July 31, 2015, and February 15, 2018, of whom 216 were assigned to the intervention group and 218 to the control group. Seventy-three patients (33.8%) developed at least one episode of VAP within 28 days following the tracheal intubation in the intervention group compared with 64 patients (29.4%) in the control group (adjusted subdistribution hazard ratio, 0.96; 95% CI, 0.76-1.20; P = .71). No serious adverse events related to the use of the pneumatic device were noted.
INTERPRETATION
Continuous regulation of cuff pressure of the tracheal tube using a pneumatic device was not superior to routine care in preventing VAP in patients with severe trauma.
CLINICAL TRIAL REGISTRATION
ClinicalTrials.gov; No.: NCT02534974; URL: www.clinicaltrials.gov.

Identifiants

pubmed: 33727034
pii: S0012-3692(21)00481-5
doi: 10.1016/j.chest.2021.03.007
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02534974']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

499-508

Investigateurs

Guillaume Besch (G)
Bélaid Bouhemad (B)
Elodie Caumon (E)
Thien-Nga Chamaraux-Tran (TN)
Raphael Cinotti (R)
Thomas Gaillard (T)
Soizic Gergaud (S)
Marc Ginet (M)
Philippe Gouin (P)
Florian Grimaldi (F)
Pierre-Gildas Guitard (PG)
Emmanuelle Hammad (E)
Lilit Kelesyan (L)
Sébastien Leduc (S)
Maxime Leger (M)
Pierre-Olivier Ludes (PO)
Laurent Muler (L)
Abdelouaid Nadji (A)
Catherine Paugam-Burtz (C)
Marie-Héléne Po (MH)
Hervé Quintard (H)
Claire Roger (C)
Antoine Roquilly (A)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Nicolas Marjanovic (N)

Service des Urgences et SAMU 86 Centre 15, CHU de Poitiers, France; Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM CIC1402 Team 5 Acute Lung Injury and Ventilatory Support, Pharmacologie des Agents anti-infectieux, France.

Matthieu Boisson (M)

Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.

Karim Asehnoune (K)

Service d'Anesthésie-Réanimation chirurgicale, CHU de Nantes, France.

Arnaud Foucrier (A)

Anesthésie-Réanimation, AP-HP Nord Hôpital Beaujon, France.

Sigismond Lasocki (S)

Département d'Anesthésie-Réanimation, CHU d'Angers, France.

Carole Ichai (C)

Service de Réanimation Polyvalente, CHU de Nice, France.

Marc Leone (M)

Aix Marseille Université, Service d'Anesthésie et de Réanimation, Assistance Publique Hôpitaux Universitaires de Marseille, Hôpital Nord, France.

Julien Pottecher (J)

Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Service d'Anesthésie-Réanimation & Médecine Péri-Opératoire, Strasbourg, France; Université de Strasbourg, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France.

Jean-Yves Lefrant (JY)

EA 2992 IMAGINE, Université de Montpellier, Montpellier, France; Pôle Anesthésie Réanimation Douleur Urgences, CHU Nîmes, France.

Dominique Falcon (D)

Pole Anesthésie Réanimation, CHU de Grenoble, France.

Benoit Veber (B)

Surgical Intensive Care Unit, Rouen University Hospital, France.

Russell Chabanne (R)

Department of Perioperative Medicine, Neurocritical Care Unit, Neuro-Anesthesiology Clinic, CHU de Clermont-Ferrand, France.

Claire-Marie Drevet (CM)

Department of Anesthesiology and Intensive Care, CHU Dijon, France.

Sébastien Pili-Floury (S)

Department of Anesthesiology and Intensive Care Medicine, CHU de Besancon, Besançon, France; EA3920 and SFR-FED 4234 INSERM, Université de Franche-Comté, Besançon, France.

Claire Dahyot-Fizelier (C)

Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.

Thomas Kerforne (T)

Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.

Sabrina Seguin (S)

Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France.

Joe de Keizer (J)

Plateforme Méthodologie-Biostatistique-Data-Management, CHU de Poitiers, France.

Denis Frasca (D)

Université de Poitiers, Faculté de Médecine, Poitiers, France; Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU de Poitiers, France; INSERM U1246, Methods in Patients-centered outcomes and Health Research-SPHERE, Nantes, France.

Jérémy Guenezan (J)

Service des Urgences et SAMU 86 Centre 15, CHU de Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France.

Olivier Mimoz (O)

Service des Urgences et SAMU 86 Centre 15, CHU de Poitiers, France; Université de Poitiers, Faculté de Médecine, Poitiers, France; INSERM U1070, Pharmacologie des Agents anti-infectieux, France. Electronic address: Olivier.mimoz@chu-poitiers.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH